Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Chain-of-verification prompting for NIH stroke scale extraction using small and frontier large language models.

International journal of medical informatics·2026

Same author

Prompt-Induced Diagnostic Bias in Large Language Model Classification of Echocardiography Reports.

The American journal of cardiology·2026

Same author

Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.

European heart journal·2026

Same author

Door-to-Electrocardiogram Time Disparities in Acute Coronary Syndrome: Predictors and Clinical Outcomes in a Contemporary Community Hospital Cohort.

Critical pathways in cardiology·2026

Same author

Specificity versus inclusivity in blood donor appeals among ethnic minority communities: The risks of "othering".

Health psychology : official journal of the Division of Health Psychology, American Psychological Association·2026

Same author

European Society of Cardiology: cardiovascular disease statistics 2025.

European heart journal·2026

Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026

Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia. Reply.

The New England journal of medicine·2026

Same journal

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

The New England journal of medicine·2026

Same journal

Hypertension Control in Low-Income Patients. Reply.

The New England journal of medicine·2026

Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026

Same journal

Hypertension Control in Low-Income Patients.

The New England journal of medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 14, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Assessment of a Polygenic Risk Score in Screening for Prostate Cancer.

Jana K McHugh^1,2, Elizabeth K Bancroft^1,2, Edward Saunders¹

¹Institute of Cancer Research, London.

The New England Journal of Medicine

|April 11, 2025

Summary

This summary is machine-generated.

Polygenic risk scores identify individuals at high risk for prostate cancer, leading to earlier detection of clinically significant disease. This approach improves upon traditional prostate cancer screening methods like PSA testing and MRI alone.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

Related Experiment Videos

Last Updated: May 14, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

Area of Science:

Oncology
Genetics
Medical Imaging

Background:

Increasing incidence of prostate cancer globally.
Limitations of prostate-specific antigen (PSA) screening, including high false positive rates.
Identification of common germline variants for prostate cancer risk prediction.

Purpose of the Study:

To evaluate the efficacy of polygenic risk scores in identifying individuals for targeted prostate cancer screening.
To compare the detection rate of clinically significant prostate cancer using polygenic risk scores versus conventional screening methods.

Main Methods:

Recruitment of men aged 55-69 from UK primary care centers.
Calculation of polygenic risk scores using 130 known prostate cancer risk variants from germline DNA.
Targeted screening with multiparametric MRI and biopsy for individuals in the top decile of polygenic risk.

Main Results:

Prostate cancer detected in 40% of screened participants with high polygenic risk scores.
A significant proportion of detected cancers (55.1%) were intermediate or higher risk, requiring treatment.
The polygenic risk score approach identified cancers missed by current UK screening pathways (PSA and MRI).

Conclusions:

Polygenic risk score-guided screening identifies a higher percentage of clinically significant prostate cancer.
This strategy enhances detection compared to PSA testing or MRI alone.
Polygenic risk scores represent a promising tool for personalized prostate cancer screening.